LQCL2415 - CMLE - Chronic Lymphocytic Leukemia With Development of CD3-Negative T-Cell Leukemia and TCL1 Rearrangements-Chronic Lymphocytic Leukemia With Development of CD3-Negative T-Cell Leukemia and TCL1 Rearrangements

Chronic Lymphocytic Leukemia With Development of CD3-Negative T-Cell Leukemia and TCL1 Rearrangements

Pdf Summary

Chronic lymphocytic leukemia (CLL) is a prevalent blood cancer affecting mostly older individuals, characterized by the proliferation of malignant B cells. The disease may present with lymphocytosis, anemia, and thrombocytopenia. In some cases, CLL can transform into a more aggressive form known as prolymphocytic leukemia (PLL), with mutations such as TCL1 rearrangement playing a key role in its pathogenesis. Diagnosis of CLL involves sustained lymphocytosis and immunophenotyping, while differentiation from PLL can be made through flow cytometry. Treatment options for CLL vary based on factors like age and prognostic mutations, with watchful waiting often recommended for early-stage cases. Prolymphocytic leukemia is a rare and severe subtype of leukemia with two forms: B-cell PLL and T-cell PLL, the latter having a worse prognosis. T-PLL is predominantly seen in older adults, with symptoms mirroring CLL. Chromosomal abnormalities, including TCL1 rearrangements, are common in T-PLL patients and are being targeted in novel therapies. In summary, CLL and PLL are related diseases with distinct characteristics, diagnosis methods, and treatment approaches, with ongoing research aiming to improve outcomes for patients.

Keywords

Chronic lymphocytic leukemia

CLL

Blood cancer

Malignant B cells

Prolymphocytic leukemia

PLL

TCL1 rearrangement

Immunophenotyping

Flow cytometry

Watchful waiting